AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18223378 — intervention group
Group type: COMPARATOR
Intervention: Standard infant formula
Number of subjects: 60
Study 16611656 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care (IC; n = 65; age mean+/‐sd 70+/‐9 yrs; FEV(1) 1.1+/‐0.5 L, 43% predicted)
Number of subjects: 155
Study 16611656 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC; n = 90; age 72+/‐9 yrs; FEV(1) 1.1+/‐0.05 L, 41% pred)
Number of subjects: 155
Study 16611656 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care (IC)
Number of subjects: 155
Study 14571611 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative medical treatment (IMT) with serial Chinese recipes and western medicine
Number of subjects: 85
Study 14571611 — intervention group
Group type: COMPARATOR
Intervention: Western medicine alone (control group)
Number of subjects: 85
Study 11028724 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion of bupivacaine/fentanyl (EPI group)
Number of subjects: 77
Study 11028724 — intervention group
Group type: COMPARATOR
Intervention: Conventional analgesic regimen (intramuscular oxycodone, OPI group)
Number of subjects: 77
Study 9343116 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg tolcapone tid
Number of subjects: 177
Study 9343116 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg tolcapone tid
Number of subjects: 177
Study 9343116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study 8363071 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bolus of 75 micrograms clonidine
Number of subjects: 7
Study 8363071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 3466377 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraligamental anaesthesia
Number of subjects: 26
Study 3466377 — intervention group
Group type: COMPARATOR
Intervention: Control surfaces (no anaesthesia)
Number of subjects: 26
Study 29070768 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy for 24 weeks
Number of subjects: 9
Study 29070768 — intervention group
Group type: COMPARATOR
Intervention: Control group (pituitary disease without GH deficiency), n=8
Number of subjects: 9
Study 27181422 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg
Number of subjects: 182
Study 27181422 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 25563708 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 96
Study 25563708 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative arrhythmia burden
Number of subjects: 96
Study 25563708 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of the longest episode of AF
Number of subjects: 96
Study 25563708 — intervention group
Group type: EXPERIMENTAL
Intervention: AF load
Number of subjects: 96
Study 23278870 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tranexamic acid (TA) combined with low-fluence 1064-nm QSNY laser treatment for melasma, taken for 8 weeks.
Number of subjects: 48
Study 23278870 — intervention group
Group type: COMPARATOR
Intervention: Low-fluence 1064-nm QSNY laser treatment for melasma (control group).
Number of subjects: 48
Study 20977582 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein meal (860 kJ, 21 g protein, 0.7 g fat, 29.6 g carbohydrate) ingested immediately prior to resistance training (RT)
Number of subjects: 34
Study 20977582 — intervention group
Group type: COMPARATOR
Intervention: High-protein meal (860 kJ, 21 g protein, 0.7 g fat, 29.6 g carbohydrate) ingested at least 2 hours following resistance training (RT)
Number of subjects: 34
Study 20977582 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (immediate and delayed protein ingestion)
Number of subjects: 34
Study 18642658 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccine
Number of subjects: 360
Study 18642658 — intervention group
Group type: COMPARATOR
Intervention: Control (2HRZ/4HR chemotherapy)
Number of subjects: 360
Study 16896999 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril therapy (ACE inhibitor)
Number of subjects: 0
Study 12510038 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg of intravenous natalizumab per kilogram
Number of subjects: 213
Study 12510038 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg of intravenous natalizumab per kilogram
Number of subjects: 213
Study 12510038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study 10939785 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (ACE inhibitor) and indapamide (diuretic) for those without contraindications
Number of subjects: 6105
Study 10939785 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo(s)
Number of subjects: 6105
Study 8865870 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized urea kinetic model (PACK‐PD) for calculating prescription parameters for peritoneal urea clearance (pKpt/V).
Number of subjects: 88
Study 8865870 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of delivered Kpt/V (dKpt/V) over one to 24 months.
Number of subjects: 88
Study 8865870 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent measurement and adjustment of pKpt/V as needed.
Number of subjects: 88
Study 1476285 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin (PEA)
Number of subjects: 12
Study 1476285 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin and low molecular weight hydroxyethylstarch (Elohes) (PEA+E)
Number of subjects: 12
Study 1476285 — intervention group
Group type: COMPARATOR
Intervention: Both groups pooled together
Number of subjects: 12
Study 6727656 — intervention group
Group type: EXPERIMENTAL
Intervention: h‐PRL induced by oral priming with 10 mg metoclopramide (MET)
Number of subjects: 8
Study 6727656 — intervention group
Group type: COMPARATOR
Intervention: normoprolactinemia (n‐PRL) after oral priming with placebo
Number of subjects: 8
Study 30876432 — intervention group
Group type: EXPERIMENTAL
Intervention: rIPostC (twice daily exposure to four cycles of 5-min cuff inflation to > 20 mmHg above systolic blood pressure)
Number of subjects: 200
Study 30876432 — intervention group
Group type: COMPARATOR
Intervention: Sham conditioning (twice daily exposure to four cycles of 5-min cuff inflation to 50 mmHg)
Number of subjects: 200
Study 30876432 — intervention group
Group type: EXPERIMENTAL
Intervention: rIPostC
Number of subjects: 200
Study 30876432 — intervention group
Group type: COMPARATOR
Intervention: Sham conditioning
Number of subjects: 200
Study 30396470 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary assessment and decision making process regarding amputation
Number of subjects: 0
Study 30396470 — intervention group
Group type: EXPERIMENTAL
Intervention: Amputation (if decided)
Number of subjects: 0
Study 30396470 — intervention group
Group type: EXPERIMENTAL
Intervention: No amputation (if decided)
Number of subjects: 0
Study 27645352 — intervention group
Group type: EXPERIMENTAL
Intervention: GNbAC1 6 mg/kg
Number of subjects: 260
Study 27645352 — intervention group
Group type: EXPERIMENTAL
Intervention: GNbAC1 12 mg/kg
Number of subjects: 260
Study 27645352 — intervention group
Group type: EXPERIMENTAL
Intervention: GNbAC1 18 mg/kg
Number of subjects: 260
Study 27645352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study 25227078 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG neurofeedback (NF) training
Number of subjects: 0
Study 25227078 — intervention group
Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 0
Study 22855341 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet enriched with virgin olive oil (MedDiet+VOO)
Number of subjects: 127
Study 22855341 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet enriched with nuts (MedDiet+nuts)
Number of subjects: 127
Study 22855341 — intervention group
Group type: COMPARATOR
Intervention: Low‐fat control diet
Number of subjects: 127
Study 20138255 — intervention group
Group type: EXPERIMENTAL
Intervention: D1 receptor antagonist [(11)C]SCH23390
Number of subjects: 40
Study 20138255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 20138255 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 40
Study 17912528 — intervention group
Group type: EXPERIMENTAL
Intervention: Covered urethroplasty (CU group) with a vascularized subcutaneous ventral flap
Number of subjects: 130
Study 17912528 — intervention group
Group type: COMPARATOR
Intervention: Non-covered urethroplasty (NCU group)
Number of subjects: 130
Study 16207776 — intervention group
Group type: EXPERIMENTAL
Intervention: High self-esteem, highly contingent targets under ego threat
Number of subjects: 0
Study 16207776 — intervention group
Group type: EXPERIMENTAL
Intervention: Low self-esteem, highly contingent targets under ego threat
Number of subjects: 0
Study 16207776 — intervention group
Group type: COMPARATOR
Intervention: Partners of high self-esteem targets
Number of subjects: 0
Study 12021622 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate plus AED inducers (Group A)
Number of subjects: 116
Study 12021622 — intervention group
Group type: COMPARATOR
Intervention: Topiramate plus AED noninducers (Group B)
Number of subjects: 116
Study 12021622 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (both groups)
Number of subjects: 116
Study 10406047 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) therapy
Number of subjects: 22
Study 10406047 — intervention group
Group type: COMPARATOR
Intervention: Mechanical ventilation (MV) alone
Number of subjects: 22
Study 10406047 — intervention group
Group type: COMPARATOR
Intervention: Healthy control infants
Number of subjects: 22
Study 10406047 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants with interstitial lung disease (ILD)
Number of subjects: 22
Study 7750669 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg cisapride
Number of subjects: 10
Study 7750669 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg cisapride
Number of subjects: 10
Study 7750669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1412112 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hydrocortisone 50 mg every six hours for 48 hours followed by oral prednisone (20 mg/day)
Number of subjects: 66
Study 1412112 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hydrocortisone 100 mg every six hours for 48 hours followed by oral prednisone (40 mg/day)
Number of subjects: 66
Study 1412112 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hydrocortisone 500 mg every six hours for 48 hours followed by oral prednisone (60 mg/day)
Number of subjects: 66
Study 1412112 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (low, medium, high dose hydrocortisone)
Number of subjects: 66
Study 3998832 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented fluid replacement (2800 +/- 400 ml)
Number of subjects: 20
Study 3998832 — intervention group
Group type: COMPARATOR
Intervention: Routine fluid administration (1220 +/- 102 ml)
Number of subjects: 20
Study 31262657 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-escalation strategy (starting dose 80 mg/day orally with weekly escalation to 160 mg/day)
Number of subjects: 123
Study 31262657 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose strategy (160 mg/day orally for 21 days of a 28-day cycle)
Number of subjects: 123
Study 31262657 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-escalation strategy
Number of subjects: 123
Study 31262657 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose strategy
Number of subjects: 123
Study 29635252 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (clopidogrel and aspirin)
Number of subjects: 0
Study 29635252 — intervention group
Group type: EXPERIMENTAL
Intervention: Major allele G at rs12041331, minor allele G at rs2644592, minor allele C at rs11264580, minor allele C at rs11249454
Number of subjects: 0
Study 29635252 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor allele T at rs57731889, minor allele A at rs16863356, minor allele T at rs7634096
Number of subjects: 0
Study 26728933 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial and Error Learning (TE)
Number of subjects: 52
Study 26728933 — intervention group
Group type: EXPERIMENTAL
Intervention: Errorless Learning (EL)
Number of subjects: 52
Study 26728933 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning by Modeling with Spaced Retrieval (MR)
Number of subjects: 52
Study 26728933 — intervention group
Group type: EXPERIMENTAL
Intervention: All three learning methods
Number of subjects: 52
Study 24144654 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day
Number of subjects: 432
Study 24144654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 432
Study 22869515 — intervention group
Group type: EXPERIMENTAL
Intervention: Shockwave therapy (SW)
Number of subjects: 22
Study 20231521 — intervention group
Group type: EXPERIMENTAL
Intervention: Palosuran 125 mg BID for 4 weeks
Number of subjects: 54
Study 20231521 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 54
Study 19002405 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine (16 mg once daily)
Number of subjects: 528
Study 19002405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 528
Study 16475602 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide (CP)
Number of subjects: 98
Study 16475602 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% CP + 0.05% calcium
Number of subjects: 98
Study 16475602 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% CP + 0.1% calcium
Number of subjects: 98
Study 16475602 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% CP + 0.2% calcium
Number of subjects: 98
Study 16475602 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% CP + 0.2% fluoride
Number of subjects: 98
Study 16475602 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% CP + 0.5% fluoride
Number of subjects: 98
Study 16475602 — intervention group
Group type: COMPARATOR
Intervention: Control group (without bleaching and storage in artificial saliva)
Number of subjects: 98
Study 12518496 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Total Toothpaste
Number of subjects: 109
Study 12518496 — intervention group
Group type: COMPARATOR
Intervention: Crest Gum Care Toothpaste
Number of subjects: 109
Study 9949387 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposuction combined with Controlled Compression Therapy (CCT)
Number of subjects: 20
Study 9949387 — intervention group
Group type: COMPARATOR
Intervention: Controlled Compression Therapy (CCT) alone
Number of subjects: 20
Study 8158702 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy to the breast (XRT group)
Number of subjects: 381
Study 8158702 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (non-XRT group)
Number of subjects: 381
Study 2893864 — intervention group
Group type: COMPARATOR
Intervention: Standard TOPV (1,000,000, 100,000, and 300,000 TCID50 of types 1, 2, and 3)
Number of subjects: 441
Study 2893864 — intervention group
Group type: EXPERIMENTAL
Intervention: New formulation of TOPV (600,000 TCID50 of type 3)
Number of subjects: 441
Study 2893864 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent vaccine (300,000 TCID50 of type 3)
Number of subjects: 441
Study 30505457 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted programme
Number of subjects: 243
Study 30505457 — intervention group
Group type: COMPARATOR
Intervention: Standard programme
Number of subjects: 243
Study 27816804 — intervention group
Group type: EXPERIMENTAL
Intervention: MDCO‐216 (apoA-IMilano/POPC) at doses of 5, 10, 20, 30, or 40 mg/kg infused over 2 hours
Number of subjects: 0
Study 25896601 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-hand technique
Number of subjects: 36
Study 25896601 — intervention group
Group type: EXPERIMENTAL
Intervention: Left one-hand technique
Number of subjects: 36
Study 25896601 — intervention group
Group type: EXPERIMENTAL
Intervention: Right one-hand technique
Number of subjects: 36
Study 23690341 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mL of water
Number of subjects: 22
Study 23690341 — intervention group
Group type: COMPARATOR
Intervention: 50 mL of water
Number of subjects: 22
Study 20533627 — intervention group
Group type: EXPERIMENTAL
Intervention: iBond, Heraeus
Number of subjects: 31
Study 20533627 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeno V, Dentsply
Number of subjects: 31
Study 20533627 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluma desensitizer, Heraeus
Number of subjects: 31
Study 20533627 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifluorid 12, Voco
Number of subjects: 31
Study 20533627 — intervention group
Group type: COMPARATOR
Intervention: Placebo (water)
Number of subjects: 31
Study 18067963 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 IU natural-source vitamin E on alternate days
Number of subjects: 39876
Study 18067963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39876
Study 17161256 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 12.5 mg once-daily for 6 months
Number of subjects: 25
Study 17161256 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 25
Study 12687873 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial shock of 14 J
Number of subjects: 720
Study 12687873 — intervention group
Group type: COMPARATOR
Intervention: Full output shock energy of 31 J
Number of subjects: 720
Study 12687873 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term follow-up
Number of subjects: 720
Study 10922144 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 336
Study 9373422 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitored light intravenous sedation
Number of subjects: 300
Study 9373422 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmonitored deep intravenous sedation
Number of subjects: 300
Study 7514238 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme (ACE) inhibitors
Number of subjects: 13000
Study 3091370 — intervention group
Group type: EXPERIMENTAL
Intervention: Cis-platinum
Number of subjects: 146
Study 3091370 — intervention group
Group type: COMPARATOR
Intervention: Adriamycin
Number of subjects: 146
Study 30808207 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive care program
Number of subjects: 0
Study 30808207 — intervention group
Group type: COMPARATOR
Intervention: Nonsupported group
Number of subjects: 0
Study 28954299 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of HPV16/18 vaccine
Number of subjects: 2439
Study 28954299 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of HPV16/18 vaccine (0/6 months)
Number of subjects: 2439
Study 28954299 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of HPV16/18 vaccine (0/1 month)
Number of subjects: 2439
Study 28954299 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose of HPV16/18 vaccine
Number of subjects: 2439
Study 28954299 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated control group (UCG)
Number of subjects: 2439
Study 27168167 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular hydroxyprogesterone caproate (250 mg weekly)
Number of subjects: 145
Study 27168167 — intervention group
Group type: COMPARATOR
Intervention: Vaginal progesterone suppository (100 mg daily)
Number of subjects: 145
Study 25041740 — intervention group
Group type: EXPERIMENTAL
Intervention: LL-37 (0.5 mg/mL)
Number of subjects: 34
Study 25041740 — intervention group
Group type: EXPERIMENTAL
Intervention: LL-37 (1.6 mg/mL)
Number of subjects: 34
Study 25041740 — intervention group
Group type: EXPERIMENTAL
Intervention: LL-37 (3.2 mg/mL)
Number of subjects: 34
Study 25041740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 21933833 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (20 mg daily) for 30 days
Number of subjects: 40
Study 21933833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 20698232 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative oral nutrition with branched chain amino acids (BCAA) - 11 patients, received BCAA supplement twice daily plus a usual diet for 14 days before operation and on days 1 to 7 after operation.
Number of subjects: 24
Study 20698232 — intervention group
Group type: COMPARATOR
Intervention: Usual diet - 13 patients, received a usual diet alone.
Number of subjects: 24
Study 18166545 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal midazolam
Number of subjects: 330
Study 18166545 — intervention group
Group type: COMPARATOR
Intervention: Rectal diazepam
Number of subjects: 330
Study 18166545 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal midazolam (for children without malaria)
Number of subjects: 330
Study 18166545 — intervention group
Group type: COMPARATOR
Intervention: Rectal diazepam (for children without malaria)
Number of subjects: 330
Study 18166545 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal midazolam and Rectal diazepam
Number of subjects: 330
Study 15639168 — intervention group
Group type: EXPERIMENTAL
Intervention: PROP bitterness
Number of subjects: 49
Study 15639168 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweetness of scotch
Number of subjects: 49
Study 15639168 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater sweetness and less bitterness from sampled scotch
Number of subjects: 49
Study 15639168 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference ratings for beer
Number of subjects: 49
Study 14516884 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (PCI)
Number of subjects: 0
Study 14516884 — intervention group
Group type: COMPARATOR
Intervention: Fibrinolytic therapy
Number of subjects: 0
Study 10502866 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based questionnaires (WWW) with anonymity
Number of subjects: 0
Study 10502866 — intervention group
Group type: COMPARATOR
Intervention: Internet-based questionnaires (WWW) without anonymity
Number of subjects: 0
Study 10502866 — intervention group
Group type: COMPARATOR
Intervention: Paper-based questionnaires with nonanonymity
Number of subjects: 0
Study 10502866 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper-based questionnaires with anonymity
Number of subjects: 0
Study 8743403 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefadroxil 250 mg
Number of subjects: 36